WALTHAM, Mass., March 2, 2012 (GLOBE NEWSWIRE) -- BG Medicine Inc. (Nasdaq:BGMD) today announced that its financial results for the fourth quarter and fiscal year 2011 will be released before market open on Thursday, March 8, 2012, followed the same day by a conference call and live webcast scheduled for 8:30am ET.
The conference call may be accessed by dialing (877) 845-1016 from the U.S. and Canada, or (708) 290-1155 from international locations. The conference call will also be available via the Internet at www.bg-medicine.com
A replay of the call will be available approximately one hour following the end of the call through March 23, 2012. The replay may be accessed by dialing (800) 859-2056 within the U.S. and Canada or (404) 537-3406 from international locations, passcode 57849814. The call will be archived and accessible on the Web site for approximately 30 days.
Listeners are encouraged to login at least 15 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software.
About BG Medicine.
BG Medicine, Inc. (Nasdaq:BGMD) is a life sciences company focused on the discovery, development and commercialization of novel, biomarker-based cardiovascular diagnostics to address significant unmet medical needs, improve patient outcomes and contain healthcare costs. The Company's first commercialized product, the BGM Galectin-3™ test for use in patients with heart failure, is available in the United States and Europe. BG Medicine has also developed CardioSCORE, a blood test designed to identify individuals at high risk for near-term major cardiovascular events, such as heart attack and stroke. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.
The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352